OptiNose, Inc. (OPTN) News

OptiNose, Inc. (OPTN): $1.46

0.02 (-1.35%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

Add OPTN to Watchlist
Sign Up

Filter OPTN News Items

OPTN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

OPTN News Highlights

  • OPTN's 30 day story count now stands at 2.
  • Over the past 14 days, the trend for OPTN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DEC, DRUG and EAR are the most mentioned tickers in articles about OPTN.

Latest OPTN News From Around the Web

Below are the latest news stories about OPTINOSE INC that investors may wish to consider to help them evaluate OPTN as an investment opportunity.

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If approved, XHANCE is expected to be the first and only drug indicated for the treatment of chronic rhinosinusitis, a diagnosis which is assigned at approximately 10 million patient visits annually YARDLEY, Pa., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused

Yahoo | December 6, 2023

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023, at 3:30 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the

Yahoo | November 22, 2023

Owning 47% shares,institutional owners seem interested in OptiNose, Inc. (NASDAQ:OPTN),

Key Insights Institutions' substantial holdings in OptiNose implies that they have significant influence over the...

Yahoo | November 17, 2023

OptiNose, Inc. (NASDAQ:OPTN) Q3 2023 Earnings Call Transcript

OptiNose, Inc. (NASDAQ:OPTN) Q3 2023 Earnings Call Transcript November 9, 2023 OptiNose, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. Operator: Good day and thank you for standing by. Welcome to OptiNose Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, […]

Yahoo | November 11, 2023

OptiNose Inc (OPTN) Reports Q3 2023 Financial Results with Improved Operating Efficiency

Key Financial Highlights and Operational Updates

Yahoo | November 9, 2023

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency as SG&A and R&D expenses decreased by $32M or 33% year-to-date PDUFA goal date for XHANCE Chronic Rhinosinusitis sNDA is December 16, 2023 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients tr

Yahoo | November 9, 2023

Optinose Announces Reporting Date for Third Quarter 2023 Financial Results

Conference Call and Webcast to be held November 9, 2023, at 8:00 a.m. Eastern TimeYARDLEY, Pa., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2023 and corporate updates, before market open on Thursday, November 9, 2023. Company to Host Conference CallMembers of the Company’s leadership team will hos

Yahoo | October 27, 2023

OptiNose (OPTN) Upgraded to Buy: What Does It Mean for the Stock?

OptiNose (OPTN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | October 24, 2023

Investors in OptiNose (NASDAQ:OPTN) have unfortunately lost 87% over the last five years

While it may not be enough for some shareholders, we think it is good to see the OptiNose, Inc. ( NASDAQ:OPTN ) share...

Yahoo | October 5, 2023

Optinose to Present at the 2023 Cantor Global Healthcare Conference

YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2023 Cantor Global Healthcare Conference on September 27, 2023 at 4:45 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcas

Yahoo | September 22, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!